# Michael G Dwyer

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 186 papers | 4,718 citations | 37 h-index | 61 g-index |
| 192 ext. papers | 5,753 ext. citations | 5.1 avg, IF | 5.32 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 186 | Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. *Journal of the American College of Cardiology*, **2017**, 69, 367-377 | 15.1 | 262 |
| 185 | Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. *Archives of Neurology*, **2006**, 63, 1301-6 | | 253 |
| 184 | Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. *Journal of Neurology*, **2012**, 259, 139-46 | 5.5 | 227 |
| 183 | Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2016**, 316, 592-601 | 27.4 | 183 |
| 182 | Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. *NeuroImage*, **2012**, 59, 331-9 | 7.9 | 160 |
| 181 | Thalamic atrophy is associated with development of clinically definite multiple sclerosis. *Radiology*, **2013**, 268, 831-41 | 20.5 | 119 |
| 180 | Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. *Journal of the Neurological Sciences*, **2009**, 282, 47-54 | 3.2 | 114 |
| 179 | Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. *NeuroImage*, **2007**, 36, 1294-300 | 7.9 | 100 |
| 178 | Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. *Expert Review of Neurotherapeutics*, **2016**, 16, 777-93 | 4.3 | 94 |
| 177 | Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. *Journal of the Neurological Sciences*, **2009**, 282, 96-105 | 3.2 | 93 |
| 176 | Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. *Multiple Sclerosis Journal*, **2007**, 13, 722-30 | 5 | 81 |
| 175 | Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 181-7 | 5.5 | 77 |
| 174 | Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. *Radiology*, **2011**, 258, 562-70 | 20.5 | 74 |
| 173 | Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. *Multiple Sclerosis Journal*, **2013**, 19, 1478-84 | 5 | 71 |
| 172 | Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. *Journal of the American College of Cardiology*, **2017**, 69, 679-691 | 15.1 | 69 |
| 171 | Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. *Journal of the Neurological Sciences*, **2009**, 282, 112-9 | 3.2 | 69 |
| 170 | Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. *Multiple Sclerosis Journal*, **2016**, 22, 1327-36 | 5 | 68 |

| | | | |
|---|---|---|---|
| 169 | Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. *Journal of Clinical and Experimental Neuropsychology*, **2007**, 29, 215-23 | 2.1 | 66 |
| 168 | Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. *BMC Medicine*, **2011**, 9, 22 | 11.4 | 61 |
| 167 | The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. *Journal of Neurology*, **2008**, 255 Suppl 1, 61-74 | 5.5 | 59 |
| 166 | Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. *Journal of Magnetic Resonance Imaging*, **2012**, 36, 73-83 | 5.6 | 55 |
| 165 | Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. *Radiology*, **2016**, 281, 884-895 | 20.5 | 54 |
| 164 | A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. *Multiple Sclerosis Journal*, **2016**, 22, 1709-1718 | 5 | 54 |
| 163 | White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. *NeuroImage*, **2009**, 47, 2083-9 | 7.9 | 54 |
| 162 | Gray matter correlations of cognition in incident Parkinson's disease. *Movement Disorders*, **2010**, 25, 629-33 | 7 | 52 |
| 161 | Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. *PLoS ONE*, **2013**, 8, e53996 | 3.7 | 50 |
| 160 | Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. *Radiology*, **2018**, 289, 487-496 | 20.5 | 48 |
| 159 | Jugular venous reflux and white matter abnormalities in Alzheimer's disease: a pilot study. *Journal of Alzheimer's Disease*, **2014**, 39, 601-9 | 4.3 | 47 |
| 158 | Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 36-42 | 5 | 44 |
| 157 | Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. *NeuroImage*, **2018**, 167, 438-452 | 7.9 | 43 |
| 156 | Brain atrophy and white matter hyperintensities in early Parkinson's disease(a). *Movement Disorders*, **2009**, 24, 2233-41 | 7 | 43 |
| 155 | Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. *NeuroImage*, **2014**, 90, 207-17 | 7.9 | 42 |
| 154 | Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. *BMC Neurology*, **2011**, 11, 128 | 3.1 | 42 |
| 153 | Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. *NeuroImage*, **2007**, 36, 746-54 | 7.9 | 42 |
| 152 | Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. *NeuroImage: Clinical*, **2018**, 17, 444-451 | 5.3 | 41 |

| | | | |
|---|---|---|---|
| 151 | Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1757-1770 | 5.3 | 39 |
| 150 | Cortical atrophy and personality in multiple sclerosis. *Neuropsychology*, **2008**, 22, 432-41 | 3.8 | 39 |
| 149 | Cine cerebrospinal fluid imaging in multiple sclerosis. *Journal of Magnetic Resonance Imaging*, **2012**, 36, 825-34 | 5.6 | 37 |
| 148 | Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. *Journal of the Neurological Sciences*, **2004**, 223, 185-93 | 3.2 | 37 |
| 147 | Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. *Journal of Neuroimaging*, **2018**, 28, 490-495 | 2.8 | 35 |
| 146 | Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 1075-81 | 5.5 | 28 |
| 145 | Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. *Psychiatry Research - Neuroimaging*, **2016**, 255, 87-93 | 2.9 | 27 |
| 144 | Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. *NeuroImage: Clinical*, **2017**, 15, 769-779 | 3.3 | 27 |
| 143 | Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. *American Journal of Neuroradiology*, **2018**, 39, 642-647 | 4.4 | 26 |
| 142 | Diffusion tensor imaging alterations in patients with postconcussion syndrome undergoing exercise treatment: a pilot longitudinal study. *Journal of Head Trauma Rehabilitation*, **2015**, 30, E32-42 | 3 | 24 |
| 141 | A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. *Therapeutic Advances in Neurological Disorders*, **2010**, 3, 15-28 | 6.6 | 24 |
| 140 | Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. *NeuroImage*, **2009**, 47, 1352-62 | 7.9 | 24 |
| 139 | Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. *Journal of Neuroimaging*, **2005**, 15, 27-36 | 2.8 | 24 |
| 138 | Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 220-231 | 5 | 24 |
| 137 | Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e427 | 9.1 | 23 |
| 136 | An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). *Magnetic Resonance Imaging*, **2017**, 39, 110-122 | 2.3 | 22 |
| 135 | Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. *NeuroImage: Clinical*, **2018**, 17, 1028-1035 | 5.3 | 22 |
| 134 | Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. *Journal of Magnetic Resonance Imaging*, **2014**, 40, 1215-22 | 5.6 | 22 |

| | | | |
|---|---|---|---|
| 133 | White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. *Journal of Neuroimaging*, **2015**, 25, 754-60 | 2.8 | 22 |
| 132 | Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 567-76 | 5 | 22 |
| 131 | Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. *International Review of Neurobiology*, **2007**, 79, 475-89 | 4.4 | 22 |
| 130 | Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 541-553 | 5 | 22 |
| 129 | Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. *Multiple Sclerosis Journal*, **2019**, 25, 1243-1254 | 5 | 21 |
| 128 | Improved assessment of multiple sclerosis lesion segmentation agreement via detection and outline error estimates. *BMC Medical Imaging*, **2012**, 12, 17 | 2.9 | 21 |
| 127 | Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. *BMC Neurology*, **2013**, 13, 157 | 3.1 | 21 |
| 126 | Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. *Human Brain Mapping*, **2019**, 40, 5231-5241 | 5.9 | 20 |
| 125 | Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. *NeuroImage: Clinical*, **2018**, 18, 1007-1016 | 5.3 | 20 |
| 124 | Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. *Journal of the Neurological Sciences*, **2018**, 393, 128-134 | 3.2 | 20 |
| 123 | Influence of personality on the relationship between gray matter volume and neuropsychiatric symptoms in multiple sclerosis. *Psychosomatic Medicine*, **2013**, 75, 253-61 | 3.7 | 20 |
| 122 | Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. *Journal of Neurology*, **2019**, 266, 866-875 | 5.5 | 20 |
| 121 | Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. *American Journal of Neuroradiology*, **2018**, 39, 289-295 | 4.4 | 19 |
| 120 | Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. *European Heart Journal*, **2018**, 39, 1687-1697 | 9.5 | 19 |
| 119 | Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. *Neurology*, **2019**, 93, e611-e623 | 6.5 | 19 |
| 118 | Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. *Neurological Research*, **2008**, 30, 816-26 | 2.7 | 19 |
| 117 | Recovery of cognitive function after relapse in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 71-78 | 5 | 19 |
| 116 | Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. *Radiology*, **2019**, 293, 424-433 | 20.5 | 18 |

| | | | |
|---|---|---|---|
| 115 | Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. *Vaccines*, **2020**, 8, | 5.3 | 18 |
| 114 | Gray matter SWI-filtered phase and atrophy are linked to disability in MS. *Frontiers in Bioscience - Elite*, **2013**, 5, 525-32 | 1.6 | 18 |
| 113 | Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. *Pathophysiology*, **2011**, 18, 53-60 | 1.8 | 18 |
| 112 | Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. *NeuroImage: Clinical*, **2018**, 17, 530-540 | 5.3 | 18 |
| 111 | Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. *American Journal of Neuroradiology*, **2018**, 39, 2237-2242 | 4.4 | 18 |
| 110 | Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. *Journal of the International Neuropsychological Society*, **2016**, 22, 920-927 | 3.1 | 17 |
| 109 | A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. *Journal of Neuroimaging*, **2017**, 27, 620-629 | 2.8 | 16 |
| 108 | Aging and Brain Atrophy in Multiple Sclerosis. *Journal of Neuroimaging*, **2019**, 29, 527-535 | 2.8 | 16 |
| 107 | Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. *Journal of Neurology*, **2015**, 262, 648-53 | 5.5 | 16 |
| 106 | Longitudinal personality change associated with cognitive decline in multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 1352458517753720 | 5 | 16 |
| 105 | Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. *American Journal of Neuroradiology*, **2016**, 37, 1010-6 | 4.4 | 16 |
| 104 | White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. *Human Brain Mapping*, **2018**, 39, 3682-3690 | 5.9 | 16 |
| 103 | Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. *Journal of the Neurological Sciences*, **2014**, 338, 128-34 | 3.2 | 16 |
| 102 | Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study. *Journal of Neuroimmunology*, **2014**, 273, 58-64 | 3.5 | 16 |
| 101 | A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. *Journal of the Neurological Sciences*, **2009**, 282, 86-95 | 3.2 | 16 |
| 100 | Monitoring of radiologic disease activity by serum neurofilaments in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7, | 9.1 | 16 |
| 99 | Establishing pathological cut-offs for lateral ventricular volume expansion rates. *NeuroImage: Clinical*, **2018**, 18, 494-501 | 5.3 | 15 |
| 98 | Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. *Multiple Sclerosis Journal*, **2020**, 26, 322-332 | 5 | 14 |

| | | | |
|---|---|---|---|
| 97 | An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study. *Journal of Neuroimaging*, **2017**, 27, 339-347 | 2.8 | 13 |
| 96 | Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. *PLoS ONE*, **2014**, 9, e91098 | 3.7 | 13 |
| 95 | Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement: REFLECT II. *JACC: Cardiovascular Interventions*, **2021**, 14, 515-527 | 5 | 13 |
| 94 | Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. *Journal of Head Trauma Rehabilitation*, **2018**, 33, E24-E32 | 3 | 13 |
| 93 | Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. *Multiple Sclerosis and Related Disorders*, **2019**, 34, 103-111 | 4 | 12 |
| 92 | A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. *American Journal of Neuroradiology*, **2019**, 40, 446-452 | 4.4 | 12 |
| 91 | Brain atrophy measurements should be used to guide therapy monitoring in MS - YES. *Multiple Sclerosis Journal*, **2016**, 22, 1522-1524 | 5 | 12 |
| 90 | Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study. *Human Brain Mapping*, **2018**, 39, 4007-4017 | 5.9 | 12 |
| 89 | Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7, | 9.1 | 12 |
| 88 | Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlas- and voxel-based analyses (VBA). *Journal of Magnetic Resonance Imaging*, **2017**, 46, 1474-1484 | 5.6 | 11 |
| 87 | Immunologic and MRI markers of the therapeutic effect of IFN-β1a in relapsing-remitting MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2015**, 2, e176 | 9.1 | 11 |
| 86 | Regional specificity of magnetization transfer imaging in multiple sclerosis. *Journal of Neuroimaging*, **2008**, 18, 130-6 | 2.8 | 11 |
| 85 | A randomized evaluation of the TriGuard HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. *European Heart Journal*, **2021**, 42, 2670-2679 | 9.5 | 11 |
| 84 | Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R* - A pilot study in patients with multiple sclerosis and normal controls. *NeuroImage*, **2019**, 186, 308-320 | 7.9 | 11 |
| 83 | Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. *American Journal of Neuroradiology*, **2018**, 39, 1480-1486 | 4.4 | 11 |
| 82 | Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. *Journal of Comparative Effectiveness Research*, **2019**, 8, 305-316 | 2.1 | 10 |
| 81 | Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the TheilerÃ¢Â€Â™s Murine Encephalomyelitis Virus mouse model of multiple sclerosis. *PLoS ONE*, **2017**, 12, e0182729 | 3.7 | 10 |
| 80 | Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement: Insights From the SENTINEL Trial. *JACC: Cardiovascular Interventions*, **2018**, 11, 384-392 | 5 | 10 |

| | | | |
|---|---|---|---|
| 79 | Effects of diet on brain iron levels among healthy individuals: an MRI pilot study. *Neurobiology of Aging*, **2015**, 36, 1678-1685 | 5.6 | 10 |
| 78 | Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. *Neurological Research*, **2012**, 34, 761-9 | 2.7 | 10 |
| 77 | Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 298-304 | 4 | 10 |
| 76 | Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson₿ disease, mild cognitive impairment, Alzheimer₿ disease, and elderly healthy controls. *Neurobiology of Aging*, **2020**, 90, 84-92 | 5.6 | 9 |
| 75 | Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. *BMC Neurology*, **2015**, 15, 232 | 3.1 | 9 |
| 74 | Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. *Human Brain Mapping*, **2014**, 35, 53-60 | 5.9 | 9 |
| 73 | Application of hidden Markov random field approach for quantification of perfusion/diffusion mismatch in acute ischemic stroke. *Neurological Research*, **2008**, 30, 827-34 | 2.7 | 9 |
| 72 | Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 245-252 | 5 | 9 |
| 71 | Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI. *Human Brain Mapping*, **2021**, 42, 1463-1474 | 5.9 | 9 |
| 70 | Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. *Journal of Neuroimaging*, **2020**, 30, 523-530 | 2.8 | 8 |
| 69 | Fingolimod₿ Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. *Journal of Neuroimaging*, **2018**, 28, 399-405 | 2.8 | 8 |
| 68 | Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. *Pathophysiology*, **2011**, 18, 61-8 | 1.8 | 8 |
| 67 | Regionally distinct white matter lesions do not contribute to regional gray matter atrophy in patients with multiple sclerosis. *Journal of Neuroimaging*, **2011**, 21, 210-8 | 2.8 | 8 |
| 66 | Olfactory identification deficit predicts white matter tract impairment in Alzheimer₿ disease. *Psychiatry Research - Neuroimaging*, **2017**, 266, 90-95 | 2.9 | 7 |
| 65 | Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders. *CNS Drugs*, **2019**, 33, 1073-1086 | 6.7 | 7 |
| 64 | Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. *Journal of Neuroimaging*, **2020**, 30, 342-350 | 2.8 | 7 |
| 63 | MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. *BMC Neurology*, **2014**, 14, 131 | 3.1 | 7 |
| 62 | Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. *Neurological Research*, **2012**, 34, 793-801 | 2.7 | 7 |

| | | | |
|---|---|---|---|
| 61 | Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis. *Neurological Research*, **2006**, 28, 275-9 | 2.7 | 7 |
| 60 | Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. *Journal of Clinical Medicine*, **2019**, 8, | 5.1 | 6 |
| 59 | Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study. *Clinical Neurology and Neurosurgery*, **2013**, 115 Suppl 1, S42-8 | 2 | 6 |
| 58 | Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. *BMC Neurology*, **2015**, 15, 135 | 3.1 | 6 |
| 57 | MRI characteristics of familial and sporadic multiple sclerosis patients. *Multiple Sclerosis Journal*, **2013**, 19, 1145-52 | 5 | 6 |
| 56 | Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. *Multiple Sclerosis International*, **2013**, 2013, 231345 | 1.1 | 6 |
| 55 | A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. *Journal of Neurology*, **2020**, 267, 802-811 | 5.5 | 6 |
| 54 | MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. *Expert Review of Neurotherapeutics*, **2020**, 20, 821-834 | 4.3 | 6 |
| 53 | Transcatheter aortic valve replacement: perioperative stroke and beyond. *Expert Review of Neurotherapeutics*, **2017**, 17, 327-334 | 4.3 | 5 |
| 52 | The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. *Journal of Neuroimaging*, **2015**, 25, 989-95 | 2.8 | 5 |
| 51 | Late onset multiple sclerosis is associated with more severe ventricle expansion. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102588 | 4 | 5 |
| 50 | Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 65-73 | 4 | 5 |
| 49 | Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 1433-1436 | 5 | 5 |
| 48 | A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. *Therapeutic Advances in Neurological Disorders*, **2015**, 8, 59-70 | 6.6 | 4 |
| 47 | A preliminary investigation of cognitive intolerance and neuroimaging among adolescents returning to school after concussion. *Brain Injury*, **2020**, 34, 818-827 | 2.1 | 4 |
| 46 | The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. *Journal of Neuroimaging*, **2018**, 28, 328-337 | 2.8 | 4 |
| 45 | Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. *Frontiers in Bioscience - Elite*, **2012**, 4, 1496-504 | 1.6 | 4 |
| 44 | Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. *Brain*, **2021**, 144, 1974-1984 | 11.2 | 4 |

| | | | |
|---|---|---|---|
| 43 | Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. *BMC Neurology*, **2016**, 16, 108 | 3.1 | 4 |
| 42 | Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. *Journal of Neurology*, **2021**, 268, 169-177 | 5.5 | 4 |
| 41 | Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years. *Multiple Sclerosis Journal*, **2021**, 27, 1125-1135 | 5 | 4 |
| 40 | Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 47, 102653 | 4 | 4 |
| 39 | Interpretation of Brain Volume Increase in Multiple Sclerosis. *Journal of Neuroimaging*, **2021**, 31, 401-407 | 2.8 | 4 |
| 38 | Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. *Journal of Neuroimaging*, **2019**, 29, 615-623 | 2.8 | 3 |
| 37 | No regional gray matter atrophy differences between pediatric- and adult-onset relapsing-remitting multiple sclerosis. *Journal of Neuroimaging*, **2014**, 24, 63-7 | 2.8 | 3 |
| 36 | White Matter Hyperintensities on 1.5 and 3 Tesla Brain MRI in Healthy Individuals. *Journal of Biomedical Graphics and Computing*, **2013**, 3, | | 3 |
| 35 | Impact of tissue atrophy on high-pass filtered MRI signal phase-based assessment in large-scale group-comparison studies: a simulation study. *Frontiers in Physics*, **2013**, 1, | 3.9 | 3 |
| 34 | Comment on "no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset". *Annals of Neurology*, **2011**, 69, 1062-3; author reply 1063 | 9.4 | 3 |
| 33 | Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. *Frontiers in Neurology*, **2020**, 11, 700 | 4.1 | 3 |
| 32 | High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. *Journal of the Neurological Sciences*, **2020**, 418, 117120 | 3.2 | 3 |
| 31 | Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8, | 9.1 | 3 |
| 30 | Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study. *Journal of Magnetic Resonance Imaging*, **2021**, 53, 731-739 | 5.6 | 3 |
| 29 | Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. *Multiple Sclerosis Journal*, **2021**, 27, 1077-1087 | 5 | 3 |
| 28 | Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. *Journal of Neurology*, **2021**, 268, 2578-2588 | 5.5 | 3 |
| 27 | Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI. *BMC Medical Imaging*, **2013**, 13, 29 | 2.9 | 2 |
| 26 | Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 2001-2013 | 5 | 2 |

| | | | |
|---|---|---|---|
| 25 | Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. *Therapeutic Advances in Neurological Disorders*, **2020**, 13, 1756286420970754 | 6.6 | 2 |
| 24 | Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. *American Journal of Neuroradiology*, **2020**, 41, 1577-1583 | 4.4 | 2 |
| 23 | Staging and stratifying cognitive dysfunction in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211011390 | 5 | 1 |
| 22 | Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. *NeuroImage: Clinical*, **2021**, 31, 102705 | 5.3 | 2 |
| 21 | DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis. *NeuroImage: Clinical*, **2021**, 30, 102652 | 5.3 | 2 |
| 20 | Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. *Journal of Neuroimmunology*, **2015**, 281, 44-50 | 3.5 | 1 |
| 19 | Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRI-based Decoupling of Complex Relationships. *Radiology*, **2019**, 292, 458-459 | 20.5 | 1 |
| 18 | Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study. *International Journal of Molecular Sciences*, **2012**, 13, 5659-73 | 6.3 | 1 |
| 17 | Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. *Fluids and Barriers of the CNS*, **2020**, 17, 9 | 7 | 1 |
| 16 | Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. *Multiple Sclerosis Journal*, **2021**, 13524585211049397 | 5 | 1 |
| 15 | Functional network dynamics and decreased conscientiousness in multiple sclerosis. *Journal of Neurology*, **2021**, 1 | 5.5 | 1 |
| 14 | Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. *Diagnostics*, **2020**, 10, | 3.8 | 1 |
| 13 | Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. *Journal of Neurology*, **2021**, 268, 4796-4808 | 5.5 | 1 |
| 12 | Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. *Journal of Neuroimaging*, **2021**, 31, 995-1002 | 2.8 | 1 |
| 11 | Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. *Experimental Neurology*, **2021**, 335, 113488 | 5.7 | 1 |
| 10 | Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. *NeuroImage: Clinical*, **2021**, 29, 102554 | 5.3 | 1 |
| 9 | Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. *Neurodegenerative Disease Management*, **2021**, 11, 329-340 | 2.8 | 1 |
| 8 | Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis.. *Brain Imaging and Behavior*, **2022**, 1 | 4.1 | 0 |

| | | | |
|---|---|---|---|
| 7 | Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIO-Enhanced Ultrahigh-Field Imaging. *Journal of Neuroimaging*, **2020**, 30, 769-778 | 2.8 | 0 |
| 6 | Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. *NeuroImage: Clinical*, **2021**, 32, 102802 | 5.3 | 0 |
| 5 | Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211044672 | 5 | 0 |
| 4 | Time course of lesion-induced atrophy in multiple sclerosis.. *Journal of Neurology*, **2022**, 1 | 5.5 | 0 |
| 3 | Reply: Don₹ Leave the Back Door Open. *JACC: Cardiovascular Interventions*, **2018**, 11, 1420 | 5 | |
| 2 | . *Journal of the Neurological Sciences*, **2005**, 231, 103-104 | 3.2 | |
| 1 | Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.. *European Radiology*, **2022**, 1 | 8 | |